The OTC bear market continues; however, this too shall pass. We’ve been here before and will be here again. Markets go in cycles and OTC stocks aren’t immune. Matter of fact, the OTC probably sees more bull and bear markets in a year than any other market.
OTC investors are failing to realize that there are still plenty of opportunities on the OTC Markets. Continuing to buy the dips in losers is not a winning strategy. We tell our subscribers to focus on what’s working and ignore the noise. Don’t get caught up in the diamond hands/paper hands BS. We talk about all of this in the video below.
In this article, we look at 4 OTC stocks that have defied the current bear market environment. The OTC stocks are Industrial Nanotech, Inc (OTCPK: INTK), Oncology Pharma Inc (OTCPK: ONPH), United Communications Partners Inc (OTCPK: UCPA), and Universal Systems, Inc (OTCPK: UVSS).
OTC STOCKS #1 INTK
Industrial Nanotech, Inc has been moving horizontally since mid-January, but it continues the bullish path on larger timeframes. The Pink Current stock is up 10% over the month to trade at $0.022. The first time we paid attention to INTK was in October last year, when the stock was trading at $0.012. The price peaked last month at over three pennies before correcting. Nevertheless, the bullish momentum is there and two pennies is a good entry point.
INTK develops sustainable nanotechnology-based solutions designed to save energy, protect assets, and reduce carbon footprints. The company’s products are sold through a global network of distributors. The products range from protective thermal insulation and corrosion prevention coatings to asset protection, insulation and mold resistant coating for food-sensitive environments, as well as protective insulation and mold prevention coating, industrial and commercial insulation and protective coating, colors for exterior painting projects, automotive coating, and insulation for solar panels.
At the end of last year, the $68 million company provided an update, revealing several new revenue streams in 2022.
On Monday, INTK announced a new deal that could generate hundreds of millions USD in revenue. The company said that it had reached an agreement with a railroad tank car owner to provide thermal insulation for the tank cars they own and operate. They will also be the exclusive distributor to the railroad tank car industry globally. Additional details on the new partner will be disclosed in an upcoming joint press release.
The initial focus will be on 9300 cars. There are approximately 500,000 tank cars in the US. The revenue to the company per tank car is about $35,000.
INTK CEO and CTO Stuart Burchill said:
“This is a market we are uniquely qualified to benefit. Railroad tank cars are limited by the Department of Transportation with regard to weight, length, width, and height. By replacing the existing insulation with a thinner and lighter insulation, we increase the volume and weight available for product carried per tank car, with no increase in cost per mile of transport distance. For this industry, our product will pay for itself in weeks.”
The company is looking to hire three more sales representatives to meet the demand.
This deal alone is capable to push the share price above $0.1 in the near future and the get closer to the $1 mark. We feel INTK is a great bet and two pennies will soon be a thing of the past.
— Early Retiree (@early_retired7) February 14, 2022
OTC STOCKS #2 ONPH
Oncology Pharma Inc is a great OTC stock that is recovering from a recent multi-month low. The Pink Current stock bottomed out in mid-December at less than $3. Now ONPH is not even a penny stock, as it broke above the $5 mark last week and now trades at $5.9, up 28% over the past five trading sessions.
Our subscribers and readers are already familiar with ONPH from our posts that mention Regen BioPharma (OTCMKTS: RGBP), a great OTC stock with long-term potential. We also discussed ONPH separately right after it reached the 1-year low in December.
RGBP signed two deals with Oncology – one deal focuses on treating pancreatic cancer, and the other one is between Regen’s subsidiary KCL Therapeutics, Inc, and Oncology for the treatment of colon cancer.
In fact, the latest price increase is also related to RGBP. On Monday, ONPH said that it plans to work with RGBP to fast track the development of therapeutic uses related to treatment in humans with pancreatic cancer of Regen’s patented antigen specific mRNA cellular cancer vaccines.
In April last year, ONPH was granted an exclusive right and license for the development and commercialization of the mRNA Vaccines for the treatment in humans of pancreatic cancer.
Now the company wants to get the green light from the FDA to conduct studies, with Regen providing the scientific expertise, laboratory access and modified mRNA and cellular manufacturing needed to complete the studies and ONPH providing the required financing. This patented technology (patent issued in August 2021) is a cellular vaccine that uses a modified mRNA molecule expressing peptides of Survivin which are exposed to dendritic cells. These dendritic cells are then matured and infused into the cancer patient’s circulation where they are expected to hone in on the cancer and destroy it. There are currently several clinical trials ongoing around the world using Survivin as a vaccine for multiple different cancers which further supports this approach.
— Coach Taylor (@CoachTaylor_OTC) February 14, 2022
ONPH CEO Charles Wagner said:
“Due to the COVID pandemic, the FDA now understands the excellent safety profile of modified mRNA technology,” says the CEO of ONPH. “We believe this technology which targets Survivin and uses the patient’s own immune system to kill their tumors will have the same success in treating pancreatic cancer that the CAR-T cell approach is having in liquid tumors.”
Other than that, OPNH is working on several projects in parallel. Last month, it released a New Year update, announcing the advancement of its relationship and further investment into Ribeira Solutions’ Connect2Med, a patient engagement platform utilizing latest available technologies. It also continues to work with NanoSmart, saying that advancement continued to be made on the feasibility studies, testing and initial gathering of data of nanoemulsion formulations for dactinomycin, which is known to destroy cancer cells.
Dactinomycin was approved by the FDA more than five decades ago but has been limited in its utility due to severe toxic side effects at effective doses. ONPH believes its novel formulation currently in development can overcome this limitation by creating a safer and potentially more effective drug formulation. This formulation may also enable greater accumulation of the drug at the tumor site, potentially increasing its tumor-kill effectiveness while simultaneously sparing healthy tissues.
ONPH used to trade above $40 during the same period last year, and we expect that this $200 million company is ready to become a billion dollar business again.
OTC STOCKS #3 UCPA
United Communications Partners Inc has been making waves this month. The share price has surged by 400% during the last five days alone to trade at two pennies after peaking on Monday at $0.025, the highest since April 2019. The spike came amid record volumes, with over 170 million shares changing hands on Friday, up from an average than ranges between 100k and 2 million per day.
The bullish move came after investors found out that Making Science, a technology and digital marketing consultancy specializing in e-commerce and digital transformation, was acquiring 70% interest in UCP, which owns 100% of Tre Kronor Media, the full service media agency with locations in both Sweden and Denmark. Making Science will complete the acquisition pursuant to a share purchase agreement entered into between Making Science and three UCP executives who will transfer an aggregate of 1.13 billion shares to Making Science. The UCP directors will maintain their roles.
The acquisition is part of the expansion process that Making Science has been carrying out since 2020, both nationally and internationally. Earlier this month, Making Science announced the acquisition of ELLIOT, the leading Digital Agency in Georgia. These acquisitions in the first quarter of 2022 follow seven carried out in 2021 as part of the company’s organic growth strategy.
UCP Chairman Niclas Fröberg, who is CEO of Tre Kronor, said:
“Making Science offers UCP and Tre Kronor Media an ability to strengthen the current service portfolio and improve the competitive strength of the UCP group. The group can now add a full range of competences from AdTech, Data, CRM, and Google reseller status which are key to our future success as a full-service Media Agency in the Nordics.”
Making Science is a $190 million Spanish-based company listed on BME in Spain. The company is growing really fast and has partnered with giants like Meta (Facebook), Google, and Salesforce, among others.
Acquired by Digital Media company
Making Science (MAKS 22 Euro on Spanish stock exchange)
Partners with Salesforce ( $CRM $207/share) since 2020
— Niks (@nikspicks1122) February 12, 2022
The acquisition is good news for UCP’s stock, which may follow the same growth pace as Making Science.
OTC STOCKS #4 UVSS
Another Pink Current stock making similar moves is Universal Systems, Inc, which has surged over 330% during the last five trading days to trade at $0.034. On Monday, the price broke above the four penny mark for the first time on record, with the stock being listed for more than a decade.
The $5 million company is promoting itself as a multi-media production company that provides brand influence to the consumer through film, television, and products.
Last year, UVSS’ parent Critical Solutions, Inc. (OTC Pink: CSLI) completed its merger of MKH Ventures Inc into CSLI, getting rid of the Shell designation. CSLI said last month that UVSS, which is seeking to change its name to Digital Distro, had secured additional production credits in a second firm project with a production team that has experience with sales and distribution directly to Netflix.
Investors are excited about UVSS as it plans to tap into the non-fungible tokens (NFTs) market. UVSS is building a Power-Management Team to create a space on the NFT Crypto markets. It will start by completing the white papers and tokenomics overviews in the Music and Entertainment Industry that it serve.
UVSS boss is Andrew Lane, a multi-platinum music producer. We found out that he’s a guy with many connections in the entertainment industry and blockchain. He is also the head of NFTBlue, a division of M Digital Studios, Inc, a high-tech blockchain group with nearly 5 years in the blockchain and cryptocurrency space along with its investment partners.
UVSS is changing its name but it said there would be no reverse split.
Last week, UVSS said that it was looking to acquire a premium news service to compliment and announce its content (film, Music, etc) offerings. Leadership will be meeting the incoming company on February 23rd to begin the doc signing and onboarding process. The company is already operating TheDailyCrypto, a crypto and NFT news site.
— Digital Distro, Inc (@Digi_Distro) February 15, 2022
UVSS is only starting its journey in one of the fastest-growing markets, and it means a lot of opportunities for early investors.
THE FINAL NOTE
All of the 4 OTC stocks discussed today are good stocks to own. The upside is much greater than the downside at these levels.
It’s also very important to eye OTC stocks that have yet to make their explosive move. There are plenty of opportunities, and we take our time to monitor hundreds of penny stocks to buy each week, trying to find the best alerts for our subscribers.
Remember, all you need is one or two penny stocks to succeed in order to crush the market averages.
As always, good luck to all (except the shorts)!
WHEN INSIDER FINANCIAL HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no position in any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.